Phaseline

Companies › Shanghai Xinzhi BioMed

Shanghai Xinzhi BioMed: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 1; Hematology, Other; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BBM-H803
AAV vector expressing human factor VIII transgene
F8Phase 2Hemophilia AMay 2027
BBM-H901
Adeno-associated virus (AAV) vector containing human factor IX (hFIX) transgene for gene t
F9Phase 2Hemophilia BJun 2028
BBM-P002
AAV-based gene therapy delivering therapeutic gene cassette into putamen
–Phase 1PDDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06111638BBM-H803Phase 2Hemophilia AHematologyMay 2027
NCT07195825BBM-P002Phase 1PDOtherDec 2027
NCT05203679BBM-H901Phase 2Hemophilia BHematologyJun 2028

Targets

F9 (1) F8 (1)

Companies with the same targets

CSL Behring Pfizer Roche Biocad BioMarin Pharmaceutical IntraBio Baxalta now part of Shire Regeneron Pharmaceuticals Swedish Orphan Biovitrum Sinocelltech

Companies built like this

Genetix Biotherapeutics Minovia Therapeutics Juventas Cell Therapy Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.